GoodRx Holdings, Inc. (NASDAQ:GDRX - Get Free Report) saw strong trading volume on Friday . 4,341,944 shares were traded during mid-day trading, an increase of 83% from the previous session's volume of 2,372,584 shares.The stock last traded at $4.58 and had previously closed at $4.64.
Analyst Upgrades and Downgrades
Several equities analysts have weighed in on GDRX shares. Weiss Ratings reaffirmed a "hold (c-)" rating on shares of GoodRx in a report on Wednesday. Raymond James Financial downgraded shares of GoodRx from a "strong-buy" rating to an "outperform" rating in a research note on Friday, August 8th. Finally, Deutsche Bank Aktiengesellschaft restated a "hold" rating and issued a $6.00 price target on shares of GoodRx in a report on Monday, August 11th. Five investment analysts have rated the stock with a Buy rating and seven have given a Hold rating to the stock. Based on data from MarketBeat, GoodRx has a consensus rating of "Hold" and a consensus target price of $5.80.
Get Our Latest Analysis on GoodRx
GoodRx Price Performance
The company has a 50-day simple moving average of $4.22 and a 200-day simple moving average of $4.39. The stock has a market cap of $1.53 billion, a PE ratio of 43.95, a PEG ratio of 1.91 and a beta of 1.23. The company has a debt-to-equity ratio of 0.75, a current ratio of 4.21 and a quick ratio of 4.21.
GoodRx (NASDAQ:GDRX - Get Free Report) last released its quarterly earnings data on Wednesday, August 6th. The company reported $0.09 earnings per share (EPS) for the quarter, missing the consensus estimate of $0.10 by ($0.01). The business had revenue of $203.07 million during the quarter, compared to analysts' expectations of $205.72 million. GoodRx had a return on equity of 8.86% and a net margin of 4.33%.The company's revenue was up 1.2% compared to the same quarter last year. During the same quarter in the previous year, the company posted $0.08 EPS. Sell-side analysts anticipate that GoodRx Holdings, Inc. will post 0.13 EPS for the current fiscal year.
Insider Buying and Selling at GoodRx
In other news, major shareholder Equity Vii L.P. Spectrum sold 16,016 shares of the firm's stock in a transaction on Friday, September 5th. The stock was sold at an average price of $4.05, for a total value of $64,864.80. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this link. 4.53% of the stock is currently owned by corporate insiders.
Institutional Inflows and Outflows
A number of hedge funds have recently made changes to their positions in the company. Osaic Holdings Inc. increased its position in shares of GoodRx by 221.2% in the second quarter. Osaic Holdings Inc. now owns 23,713 shares of the company's stock valued at $118,000 after buying an additional 16,330 shares in the last quarter. Headlands Technologies LLC boosted its stake in shares of GoodRx by 155.7% during the second quarter. Headlands Technologies LLC now owns 37,914 shares of the company's stock valued at $189,000 after acquiring an additional 23,084 shares during the last quarter. Tower Research Capital LLC TRC increased its position in GoodRx by 202.3% during the 2nd quarter. Tower Research Capital LLC TRC now owns 11,327 shares of the company's stock worth $56,000 after purchasing an additional 7,580 shares in the last quarter. Sugar Maple Asset Management LLC purchased a new stake in GoodRx during the 2nd quarter worth about $189,000. Finally, State of Tennessee Department of Treasury purchased a new stake in GoodRx during the 2nd quarter worth about $145,000. Hedge funds and other institutional investors own 63.77% of the company's stock.
About GoodRx
(
Get Free Report)
GoodRx Holdings, Inc, together with its subsidiaries, offers information and tools that enable consumers to compare prices and save on their prescription drug purchases in the United States. The company operates a price comparison platform that provides consumers with curated, geographically relevant prescription pricing, and access to negotiated prices.
Further Reading
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.
Before you consider GoodRx, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and GoodRx wasn't on the list.
While GoodRx currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Wondering what the next stocks will be that hit it big, with solid fundamentals? Enter your email address to see which stocks MarketBeat analysts could become the next blockbuster growth stocks.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
